GlycoMimetics Inc (GLYC)
0.3994
0.00 (0.00%)
USD |
NASDAQ |
Nov 14, 16:00
0.3994
0.00 (0.00%)
After-Hours: 06:45
GlycoMimetics Free Cash Flow (Quarterly): -8.896M for June 30, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | -8.896M |
March 31, 2024 | -10.52M |
December 31, 2023 | -7.616M |
September 30, 2023 | -8.691M |
June 30, 2023 | -6.985M |
March 31, 2023 | -11.61M |
December 31, 2022 | -7.912M |
September 30, 2022 | -8.620M |
June 30, 2022 | -16.27M |
March 31, 2022 | -13.74M |
December 31, 2021 | -12.81M |
September 30, 2021 | -16.95M |
June 30, 2021 | -13.62M |
March 31, 2021 | -14.13M |
December 31, 2020 | -9.724M |
September 30, 2020 | -11.52M |
June 30, 2020 | -14.56M |
March 31, 2020 | -3.508M |
December 31, 2019 | -12.81M |
September 30, 2019 | -13.47M |
June 30, 2019 | -11.47M |
March 31, 2019 | -14.39M |
December 31, 2018 | -10.04M |
Date | Value |
---|---|
September 30, 2018 | -10.11M |
June 30, 2018 | -13.08M |
March 31, 2018 | -10.23M |
December 31, 2017 | -8.403M |
September 30, 2017 | -6.263M |
June 30, 2017 | -6.272M |
March 31, 2017 | -9.125M |
December 31, 2016 | -6.393M |
September 30, 2016 | -7.697M |
June 30, 2016 | -7.098M |
March 31, 2016 | -9.247M |
December 31, 2015 | -6.961M |
September 30, 2015 | 13.51M |
June 30, 2015 | -6.348M |
March 31, 2015 | -8.707M |
December 31, 2014 | -6.169M |
September 30, 2014 | -4.856M |
June 30, 2014 | 9.132M |
March 31, 2014 | -2.601M |
December 31, 2013 | -5.578M |
September 30, 2013 | -3.428M |
June 30, 2013 | -2.731M |
March 31, 2013 | -3.883M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-16.95M
Minimum
Sep 2021
-3.508M
Maximum
Mar 2020
-11.08M
Average
-11.52M
Median
Sep 2020
Free Cash Flow (Quarterly) Benchmarks
Biomarin Pharmaceutical Inc | 200.30M |
Arbutus Biopharma Corp | -20.74M |
Revance Therapeutics Inc | -41.15M |
FibroGen Inc | -39.88M |
Cidara Therapeutics Inc | -36.80M |